BREAST-CANCER-PATIENT-DERIVED TUMORGRAFTS

Breast cancer causes over 40,000 deaths in the United States annually. Use of patient-derived tumorgrafts improves treatment efficacy, but availability of such models is limited. Novel models for breast tumor growth and metastasis, derived from patients and engrafted directly into the mammary glands of mice, increase access to patient-derived tumorgrafts. The model promotes angiogenesis, increases tumor growth, and facilitates maintenance of ER protein levels during serial propagation. With twelve developed tumorgraft lines, the model spans all major clinical breast cancer subtypes and several of the known molecular subtypes. The tumorgrafts recapitulate spontaneous metastasis with patterns similar to those observed in the original patients and serve as a critical indicator of patient outcome.